253 related articles for article (PubMed ID: 29762040)
1. Orally Bioavailable and Effective Buparvaquone Lipid-Based Nanomedicines for Visceral Leishmaniasis.
Smith L; Serrano DR; Mauger M; Bolás-Fernández F; Dea-Ayuela MA; Lalatsa A
Mol Pharm; 2018 Jul; 15(7):2570-2583. PubMed ID: 29762040
[TBL] [Abstract][Full Text] [Related]
2. Nanoliposomal Buparvaquone Immunomodulates Leishmania infantum-Infected Macrophages and Is Highly Effective in a Murine Model.
da Costa-Silva TA; Galisteo AJ; Lindoso JA; Barbosa LR; Tempone AG
Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167544
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of liposomal buparvaquone in an experimental hamster model of Leishmania (L.) infantum chagasi.
Reimão JQ; Colombo FA; Pereira-Chioccola VL; Tempone AG
Exp Parasitol; 2012 Mar; 130(3):195-9. PubMed ID: 22281156
[TBL] [Abstract][Full Text] [Related]
4. Topical buparvaquone nano-enabled hydrogels for cutaneous leishmaniasis.
Lalatsa A; Statts L; Adriana de Jesus J; Adewusi O; Auxiliadora Dea-Ayuela M; Bolas-Fernandez F; Dalastra Laurenti M; Felipe Domingues Passero L; Serrano DR
Int J Pharm; 2020 Oct; 588():119734. PubMed ID: 32777535
[TBL] [Abstract][Full Text] [Related]
5. Oral administration of buparvaquone nanostructured lipid carrier enables in vivo activity against Leishmania infantum.
Monteiro LM; Löbenberg R; Barbosa EJ; de Araujo GLB; Sato PK; Kanashiro E; de Araujo Eliodoro RH; Rocha M; de Freitas VLT; Fotaki N; Bou-Chacra NA
Eur J Pharm Sci; 2022 Feb; 169():106097. PubMed ID: 34910988
[TBL] [Abstract][Full Text] [Related]
6. Topical buparvaquone formulations for the treatment of cutaneous leishmaniasis.
Garnier T; Mäntylä A; Järvinen T; Lawrence MJ; Brown MB; Croft SL
J Pharm Pharmacol; 2007 Jan; 59(1):41-9. PubMed ID: 17227619
[TBL] [Abstract][Full Text] [Related]
7. Statistical modeling, optimization and characterization of solid self-nanoemulsifying drug delivery system of lopinavir using design of experiment.
Patel G; Shelat P; Lalwani A
Drug Deliv; 2016 Oct; 23(8):3027-3042. PubMed ID: 26882014
[TBL] [Abstract][Full Text] [Related]
8. Nano-sized Droplets of Self-Emulsifying System for Enhancing Oral Bioavailability of Chemotherapeutic Agent VP-16 in Rats: A Nano Lipid Carrier for BCS Class IV Drugs.
Khalid N; Sarfraz M; Arafat M; Akhtar M; Löbenberg R; Ur Rehman N
J Pharm Pharm Sci; 2018; 21(1):398-408. PubMed ID: 30365396
[TBL] [Abstract][Full Text] [Related]
9. Solid self-nanoemulsifying drug delivery system (S-SNEDDS) of darunavir for improved dissolution and oral bioavailability: In vitro and in vivo evaluation.
Inugala S; Eedara BB; Sunkavalli S; Dhurke R; Kandadi P; Jukanti R; Bandari S
Eur J Pharm Sci; 2015 Jul; 74():1-10. PubMed ID: 25845633
[TBL] [Abstract][Full Text] [Related]
10. Surface-adsorbed reverse micelle-loaded solid self-nanoemulsifying drug delivery system of talinolol.
Shakeel F; Haq N; Alanazi FK; Alsarra IA
Pharm Dev Technol; 2016 Mar; 21(2):131-9. PubMed ID: 25318634
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo performance of novel supersaturated self-nanoemulsifying drug delivery systems (super-SNEDDS).
Thomas N; Holm R; Müllertz A; Rades T
J Control Release; 2012 May; 160(1):25-32. PubMed ID: 22405903
[TBL] [Abstract][Full Text] [Related]
12. Silica encapsulated lipid-based drug delivery systems for reducing the fed/fasted variations of ziprasidone in vitro.
Dening TJ; Rao S; Thomas N; Prestidge CA
Eur J Pharm Biopharm; 2016 Apr; 101():33-42. PubMed ID: 26812284
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic Evaluation of Improved Oral Bioavailability of Valsartan: Proliposomes Versus Self-Nanoemulsifying Drug Delivery System.
Nekkanti V; Wang Z; Betageri GV
AAPS PharmSciTech; 2016 Aug; 17(4):851-62. PubMed ID: 26381913
[TBL] [Abstract][Full Text] [Related]
14. Nanoemulsifying drug delivery system to improve the bioavailability of piroxicam.
Motawea A; Borg T; Tarshoby M; Abd El-Gawad AE
Pharm Dev Technol; 2017 May; 22(3):445-456. PubMed ID: 27583581
[TBL] [Abstract][Full Text] [Related]
15. Solid super saturated self-nanoemulsifying drug delivery system (sat-SNEDDS) as a promising alternative to conventional SNEDDS for improvement rosuvastatin calcium oral bioavailability.
Abo Enin HA; Abdel-Bar HM
Expert Opin Drug Deliv; 2016 Nov; 13(11):1513-1521. PubMed ID: 27564321
[TBL] [Abstract][Full Text] [Related]
16. Design and optimization of candesartan loaded self-nanoemulsifying drug delivery system for improving its dissolution rate and pharmacodynamic potential.
Verma R; Kaushik D
Drug Deliv; 2020 Dec; 27(1):756-771. PubMed ID: 32397771
[TBL] [Abstract][Full Text] [Related]
17. Solid self-nanoemulsifying drug delivery system filled in enteric coated hard gelatin capsules for enhancing solubility and stability of omeprazole hydrochloride.
Al-Nimry SS; Alkhamis KA; Altaani BM
Pharm Dev Technol; 2020 Jun; 25(5):588-600. PubMed ID: 31976799
[TBL] [Abstract][Full Text] [Related]
18. Shape mediated splenotropic delivery of buparvaquone loaded solid lipid nanoparticles.
Maithania HV; Mohanty BS; Chaudhari PR; Samad A; Devarajan PV
Drug Deliv Transl Res; 2020 Feb; 10(1):159-167. PubMed ID: 31468307
[TBL] [Abstract][Full Text] [Related]
19. Effects of solid carriers on the crystalline properties, dissolution and bioavailability of flurbiprofen in solid self-nanoemulsifying drug delivery system (solid SNEDDS).
Kang JH; Oh DH; Oh YK; Yong CS; Choi HG
Eur J Pharm Biopharm; 2012 Feb; 80(2):289-97. PubMed ID: 22119666
[TBL] [Abstract][Full Text] [Related]
20. Development of self-nanoemulsifying drug delivery systems for the enhancement of solubility and oral bioavailability of fenofibrate, a poorly water-soluble drug.
Mohsin K; Alamri R; Ahmad A; Raish M; Alanazi FK; Hussain MD
Int J Nanomedicine; 2016; 11():2829-38. PubMed ID: 27366063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
